250 likes | 371 Vues
In the first quarter of 2011, significant economic changes were observed, including interest rate increases, inflation acceleration, and growth deceleration. The company implemented strategic measures to manage costs and sales processes, revealing that 30% of sales stemmed from retail consumers while 70% were through wholesalers and distributors. Market evolution indicated a slight increase in market share, and product innovation was key, with plans for launching unique generics and relaunching established brands. Ongoing monitoring ensures targeted acquisitions and financial stability throughout the year.
E N D
InstitutionalPresentation Update | May 2011
Keymeasuresimplemented in 1Q11 • Interest rate increases • Inflationacceleration • Growthdecelaration • Maintenancelevelsofemploymentandincome Change in MacroeconomicScenario • Increasedprices • Reducedpaymentterms • Acceleratedintegrations • Reducedexpenses MeasurestakenbytheCompany
Sales Process 30% ofsales Retail Consumer HYPER WholeSaler / Distribuitor 70% ofsales Sell In Sell Out
Priceincreaseprocess Keyvariables 108% -5% -2% 60 106% -6% -3% 60 APR 104% -7% -4% 60 MAR 102% -8% -4% 60 Pricelist: Discount: Trade deals: Term: FEB 100% -10% -5% 90 JAN DEC Illustrative example, the figures are fictitious
Whatdid it happen? Lastyearwewereflexiblewiththecommercial package Atthebeginningofthisyear, wewerefirm to markthenew package conditions Manyclients, mainlytheindirects, partiallydidn´tplacetheirordersunderthenewconditions HealthySell out, Weaksell in: chaininventoriesdecreases
Sell in x Sell out x PC Inventoriylevels Sell-In x Sell-Out (3 monthsmovingaverage) R$ Million Oct/10 Nov/10 Dec/10 Jan/11 Feb/11 Mar/11 Sell In R$ Sell Out R$ TheoreticalInventory % Example for indirect clients at one of our Personal Care divisions.
Pharma – DemandEvolution in 1Q11 Market Evolution 37.2% 33.5% 14.7% 9.3% 18.0% Total Share: from 6.9% to 7.9%
Pharma – GenericsMarketEvolution MEDICAMENTOS - Mercado de Genéricos GenericMarketEvolution(volume) - Growth jan/10 feb/10 mar/10 apr/10 may/10 jun/10 jul/10 aug/10 sep/10 oct/10 nov/10 dec/10 jan/11 feb/11 HYPERMARCAS RNK (UNITS) HYPERMARCAS GENERICS MARKET
PC – KeyMarketTrends Market Trends Hyper Share * Value
Innovation 1st Q Launches 2011 Pipeline Comments • To reach 80% Top Genericsby Dec.11 • To launch “unique-Generics” • To launchMirrors, UmbrellasandInnovators Pharma 28 60 • To relaunchDenorex, Lucretin, Biorene, Aero Monange, Avanço Moband Profissional line • Relaunches: Paixão andPomPomdiapers Packagedgoods 108 >700
Ceci Project – PC Innovation Center • Product development laboratories • Studies of perception with the consumer • Market research 12
1Q11 ResultsSummary * * * * *Reference Base
Integrationupdate Potential (R$ MM) Implemented in 1Q11 (R$ MM) Target % Achieved 115 56 49% 2010 Acqusitions To finalize untilSep.11 2011 Acqusitions 135 94 70% Mantecorp To finalize until Jun.11 7 6 86% Mabesa To finalize until Jun.11 257 156 61% Overall Total To finalize 100% until Dec.11 .
Capital Structure 10 Year Bond Issuance
Leverage (R$ million) ConsidersBondsissuanceafter 1Q11 closing. Pro forma Net Debtdividedbyguidanceofminimum EBITDA of 2011 (R$ 1 billlion) 18
Organicgrowthmeasurement 2 methodologiescomparison ∆ Reference Base . ∆ SBS Net Revenues XT0 XT1
Reference Base Advantages Complete Explanation 2010 FixedBaseline ComparisonofIncomeStatementmainlines (Net Revenue, Gross Profitand EBITDA) It proves thesynergiesseizingprocess FacilitatestheResultsforecasting (quarterbyquarter)
Sensitivityanalysis Growth EBITDA Margins NEW GUIDANCE: > R$1 bi